Study workflow. Before immunophenotypic analysis, BM slides are reviewed to confirm diagnosis or posttreatment morphological remission. In cases where morphology cannot define the acute leukemia phenotype as myeloid or lymphoid, a screening study is performed by using an orientation antibody panel including CD45, CD34, myeloperoxidase, CD19, CD79a, CD3, CD7. LAIPs are defined in BM samples at diagnosis, after each course of therapy, pre–autologous stem cell transplantation, post–autologous stem cell transplantation, and every 3 months thereafter for 2 years. In addition, a sample of stem cell–enriched peripheral blood harvested for autologous transplant is analyzed.